Обновление: Обсуждения на рынке: Moderna выиграла патентный спор против Pfizer и BioNTech в немецком суде

Pharmaceutical company Pfizer is facing scrutiny over its attempts to transfer liability for vaccine side effects to countries that purchase its COVID-19 vaccine. In various agreements, Pfizer has reportedly requested that governments assume any legal liabilities that may arise from the administration of its vaccines. This has led to significant debate and concern, particularly in lower-income countries that may not have the resources to handle potential legal battles.

Moderna and BioNTech, both involved in the vaccine production process, have also been highlighted for similar liability arrangements. Moderna has stated that its agreements are consistent with established standards adopted during public health emergencies, aiming to accelerate the widespread distribution of vaccines. BioNTech expressed similar sentiments, emphasizing that their liability processes are in line with industry norms and aim to ensure a rapid and global vaccine rollout.

The issue of vaccine liability has become an essential aspect of discussions regarding the equitable distribution of vaccines worldwide. High-income countries often have the legal frameworks and financial resources to address such matters, whereas lower-income nations may find themselves at a disadvantage. This has raised concerns about global health equity and the power dynamics influencing vaccine distribution agreements.